Key Insights

Highlights

Success Rate

82% trial completion

Published Results

119 trials with published results (15%)

Research Maturity

398 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.6%

90 terminated out of 776 trials

Success Rate

81.6%

-5.0% vs benchmark

Late-Stage Pipeline

6%

46 trials in Phase 3/4

Results Transparency

30%

119 of 398 completed with results

Key Signals

119 with results82% success90 terminated

Data Visualizations

Phase Distribution

638Total
Not Applicable (109)
Early P 1 (18)
P 1 (220)
P 2 (245)
P 3 (42)
P 4 (4)

Trial Status

Completed398
Recruiting125
Terminated90
Unknown70
Active Not Recruiting42
Withdrawn23

Trial Success Rate

81.6%

Benchmark: 86.6%

Based on 398 completed trials

Clinical Trials (776)

Showing 20 of 20 trials
NCT01109394RecruitingPrimary

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT05334069Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07602777Phase 1RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

NCT06528769Phase 2Recruiting

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

NCT05944237Phase 1Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

NCT07189871Phase 1Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT03373097Phase 1Active Not Recruiting

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

NCT07847268CompletedPrimary

A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT07614620Not ApplicableRecruitingPrimary

Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer

NCT06021626Phase 1RecruitingPrimary

A Study of CRD3874-SI in People With Solid Tumors

NCT04457258Early Phase 1Active Not Recruiting

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

NCT00874874Phase 2CompletedPrimary

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery

NCT04273061Phase 2Recruiting

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

NCT07297160Phase 1Withdrawn

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

NCT06674811Recruiting

Biomarkers of Resiliency In Childhood Cancer Surgery

NCT01189643Early Phase 1Active Not RecruitingPrimary

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

NCT04577014Phase 1Recruiting

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

NCT01746238Phase 1Active Not RecruitingPrimary

Bevacizumab/Doxorubicin/Radiation for Sarcoma

Scroll to load more

Research Network

Activity Timeline